Medicus International

Belkins
Medicus International brings to our clients expertise across all areas of strategic consultancy, including market analysis, competitor intelligence.

Related News

MODERNA TAKES $1.5B CONTRACT WITH U.S. GOVT. FOR COVID-19 VACCINE

Moderna | August 13, 2020

news image

Through its COVID-19 vaccine partnership with the U.S. government, Moderna picked up nearly $1 billion in research aid. Now, it's joining a list of other companies to take a supply order from the federal government. Under a deal worth up to $1.525 billion, Moderna agreed to deliver 100 million doses of its mRNA vaccine candidate if it succeeds in late-stage testing. The deal doesn’t stipulate a timeline for vaccine shipments, at least publicly, but does include “incentive payment...

Read More

CLARUS EQUIPS TOP PHARMACEUTICAL COMPANY, ASTRAZENECA, WITH INNOVATIVE THERMOBILE BOARDS IN THE FIGHT AGAINST COVID-19

Clarus | April 22, 2020

news image

Clarus, the industry leader in glassboard innovation and creator of the new TherMobile, a non-porous mobile board that serves as a protective shield during the health screening process, is successfully supporting AstraZeneca's efforts in keeping their essential employees safe while continuing to work during the COVID-19 crisis. "We initially developed TherMobile as a way to keep our own employees safe while implementing employee temperature screening at our facility," said Marc Man...

Read More

PHARMA TECH

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics | September 13, 2021

news image

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More

FORWARDVUE PHARMA SECURES FUNDING TO ADVANCE PRE-CLINICAL DEVELOPMENT PROGRAMS

prnewswire | August 26, 2020

news image

ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. As the Founder of ForwardVue Pharma, Alan has performed 40,000+ intravitreal injections as a practicing retina specialist with over 20 years of experience. He has served as principle investigator in a number of diabetic retinopathy and AMD trials, presents his w...

Read More

Moderna | August 13, 2020

news image

MODERNA TAKES $1.5B CONTRACT WITH U.S. GOVT. FOR COVID-19 VACCINE

Through its COVID-19 vaccine partnership with the U.S. government, Moderna picked up nearly $1 billion in research aid. Now, it's joining a list of other companies to take a supply order from the federal government. Under a deal worth up to $1.525 billion, Moderna agreed to deliver 100 million doses of its mRNA vaccine candidate if it succeeds in late-stage testing. The deal doesn’t stipulate a timeline for vaccine shipments, at least publicly, but does include “incentive payment...

Read More

Clarus | April 22, 2020

news image

CLARUS EQUIPS TOP PHARMACEUTICAL COMPANY, ASTRAZENECA, WITH INNOVATIVE THERMOBILE BOARDS IN THE FIGHT AGAINST COVID-19

Clarus, the industry leader in glassboard innovation and creator of the new TherMobile, a non-porous mobile board that serves as a protective shield during the health screening process, is successfully supporting AstraZeneca's efforts in keeping their essential employees safe while continuing to work during the COVID-19 crisis. "We initially developed TherMobile as a way to keep our own employees safe while implementing employee temperature screening at our facility," said Marc Man...

Read More

PHARMA TECH

Phanes Therapeutics | September 13, 2021

news image

PHANES THERAPEUTICS REVEALS SPECPAIR™ TECHNOLOGY PLATFORM THAT ENHANCES MANUFACTURABILITY OF BISPECIFIC ANTIBODIES

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are d...

Read More

prnewswire | August 26, 2020

news image

FORWARDVUE PHARMA SECURES FUNDING TO ADVANCE PRE-CLINICAL DEVELOPMENT PROGRAMS

ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration. As the Founder of ForwardVue Pharma, Alan has performed 40,000+ intravitreal injections as a practicing retina specialist with over 20 years of experience. He has served as principle investigator in a number of diabetic retinopathy and AMD trials, presents his w...

Read More